AMLX
NASDAQ HealthcareAmylyx Pharmaceuticals, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $18.36 |
|---|---|
| 成交量 | 1,519,415 |
| 市值 | 2.03B |
| 贝塔系数 | -0.210 |
| RSI（14日） | 78.9 超买 |
| 200日均线 | $12.61 |
| 50日均线 | $14.74 |
| 52周最高 | $18.61 |
| 52周最低 | $3.94 |
| Forward P/E | -14.99 |
| Price / Book | 6.61 |
🎯 投资策略评分
AMLX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (69/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AMLX in your text
粘贴任何文章、记录或帖子 — 工具将提取 AMLX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.